{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:48:04Z","timestamp":1775227684039,"version":"3.50.1"},"reference-count":15,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2004,6,21]],"date-time":"2004-06-21T00:00:00Z","timestamp":1087776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2004,7]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold>\u2002We report a case of haemophilia A with a high responding inhibitor of factor VIII (FVIII) who had a serious retroperitoneal haematoma caused by penetration of a duodenal ulcer. Inhibitor\u2010bypassing therapy was commenced immediately on admission. On the 17th day of treatment with activated prothrombin complex concentrate (APCC; FEIBA\u00ae), re\u2010bleeding occurred and thrombelastography (TEG) demonstrated resistance to therapy. Treatment was changed to recombinant activated factor VII (rFVIIa; NovoSeven\u00ae) and resulted in clinical improvement together with an improvement in TEG parameters. On the 10th day of continuous infusion with NovoSeven\u00ae, however, TEG again showed resistance to therapy. FEIBA\u00ae infusions were re\u2010introduced and TEG results remained satisfactory for 7\u2003days. On day 34, however, further retroperitoneal bleeding was evident and a decline in the haemostatic efficiency of FEIBA\u00ae was recorded by TEG. NovoSeven\u00ae was again successfully administered for 7\u2003days. There were no laboratory findings to indicate disseminated intravascular coagulation (DIC), hypercoagulability or abnormal fibrinolysis. The plasma\u2010based clotting tests did not show any additional prolongation on the occasions when the TEG demonstrated unresponsiveness to FEIBA\u00ae or NovoSeven\u00ae. These findings suggested that some component of whole blood, other than plasma might have governed the TEG data. The long\u2010term use of APCC such as FEIBA\u00ae or rFVIIa, requires careful monitoring in terms of FVIII inhibitor bypassing activity as well as the tendency to DIC.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2004.00924.x","type":"journal-article","created":{"date-parts":[[2004,7,2]],"date-time":"2004-07-02T06:02:05Z","timestamp":1088748125000},"page":"397-400","source":"Crossref","is-referenced-by-count":67,"title":["Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life\u2010threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor"],"prefix":"10.1111","volume":"10","author":[{"given":"T.","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Shima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. C.","family":"Giddings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,6,28]]},"reference":[{"key":"e_1_2_4_2_2_2","first-page":"228","article-title":"Safety and immunogenicity of recombinant factor VIII (Recombinate) in previously untreated patients (PUPs). A 7.3\u2003year update","volume":"4","author":"Gruppo R","year":"1998","journal-title":"Haemophilia"},{"key":"e_1_2_4_2_3_2","first-page":"162","article-title":"Recombinant FVIII (Kogenate) treatment of previously untreated patients (PUPs) with hemophilia A. Update of safety, efficacy and inhibitor development after seven study years","volume":"78","author":"Lusher J","year":"1997","journal-title":"Thromb Haemost"},{"issue":"40","key":"e_1_2_4_2_4_2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1600-0609.1984.tb02564.x","article-title":"The role of prothrombin complex concentrates in the treatment of hemophiliacs with factor VIII inhibitors","volume":"33","author":"Lusher JM.","year":"1984","journal-title":"Scand J Haematol"},{"key":"e_1_2_4_2_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-199803000-00002"},{"key":"e_1_2_4_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198008213030803"},{"key":"e_1_2_4_2_7_2","first-page":"36","article-title":"Prediction and management of adverse events associated with the use of factor IX complex concentrates","volume":"30","author":"Lusher JM.","year":"1993","journal-title":"Semin Hematol"},{"key":"e_1_2_4_2_8_2","first-page":"416","article-title":"Acute myocardial infarction complicating prothrombin complex concentrate therapy in an 8\u2010year\u2010old boy with hemophilia A and factor VIII inhibitor","volume":"15","author":"Karayalcin G","year":"1993","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"e_1_2_4_2_9_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614918"},{"key":"e_1_2_4_2_10_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613284"},{"key":"e_1_2_4_2_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00532.x"},{"key":"e_1_2_4_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(81)90319-4"},{"issue":"4","key":"e_1_2_4_2_13_2","first-page":"91","article-title":"Perspectives on thromboelastography","volume":"21","author":"Caprini JA","year":"1995","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"e_1_2_4_2_14_2","first-page":"139","article-title":"Thrombelastgram as a hemostatic monitor during recombinant factor VIIa treatment in hemophilia A patients with inhibitor to factor VIII","volume":"26","author":"Yoshioka A","year":"1996","journal-title":"Haemostasis"},{"key":"e_1_2_4_2_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1977.tb02096.x"},{"key":"e_1_2_4_2_16_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613155"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2004.00924.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2004.00924.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T20:15:07Z","timestamp":1705176907000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2004.00924.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6,28]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["10.1111\/j.1365-2516.2004.00924.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2004.00924.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6,28]]}}}